SUSTAINED-RELEASE BUPRENORPHINE FORMULATIONS

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20160128997A1
SERIAL NO

14935168

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The disclosure is directed to sustained-release buprenorphine formulations that provide long-term, therapeutic levels of buprenorphine for the treatment of pain and the maintenance treatment of opioid use disorders, such as opioid dependence.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INDIVIOR UK LIMITEDTHE CHAPLEO BUILDING HENRY BOOT WAY PRIORY PARK HULL HU4 7DY

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Nasser, Azmi Richmond, US 8 15

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation